MSMC Research Program
Welcome,         Profile    Billing    Logout  
 7 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lutzky, Jose
CA224-094, NCT04552223: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Active, not recruiting
2
27
US
Nivolumab, Opdivo, Relatlimab, BMS-986016
Jose Lutzky, MD, Bristol-Myers Squibb, United States Department of Defense
Metastatic Uveal Melanoma
12/24
12/26
NCT04291105: Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Recruiting
2
87
US, RoW
VV1, VSV-IFNβ-NIS, Voyager V1, VV1, Cemiplimab, Libtayo
Vyriad, Inc., Regeneron Pharmaceuticals
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
12/24
03/25
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Completed
1/2
45
US, RoW
Modakafusp Alfa, TAK-573, Pembrolizumab
Takeda
Neoplasms, Melanoma
11/23
11/23
CA101-001, NCT04423029 / 2021-000038-33: A Study of DF6002 Alone and in Combination With Nivolumab

Recruiting
1/2
473
Europe, US, RoW
DF6002, Nivolumab, Opdivo
Dragonfly Therapeutics
Solid Tumors
07/24
12/25
NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting
1/2
159
Europe, US
TNG462
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
05/26
09/26
TS-PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Active, not recruiting
1
67
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
06/25
06/27
NCT05973487: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Recruiting
1
100
US
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
12/26
12/26
NCT05812027: A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting
N/A
650
US
Tumor and HLA Profiling
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, Melanoma, Ovarian Cancer, HPV16 Related Cancers
01/26
01/27
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting
N/A
2000
Europe, US, RoW
Plasma sample collection
OncoHost Ltd.
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma
10/29
10/29
Nunez, Yvonne
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
ImmunoGen, Inc., GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29

Download Options